Cell-based Interceptive Medicine Consortium (InterCEpt)
Cell-based Interceptive Medicine is a new medical paradigm first launched in Europe - more than 100 institutions are participating in a large-scale project called Lifetime, funded by the European Union - which aims to develop and use omics technologies (genomics, transcriptomics, proteomics, etc.) at single-cell resolution to early detect molecular disturbances that can lead to disease and develop treatments before tissue damage and symptoms are present.
To join this movement, the 37TrillionCells initiative was launched. Its mission is to improve healthcare by advancing the integration of omics to map gene expression programs at cellular resolution. The Cell-based Interceptive Medicine Consortium (InterCEpt) grew out of 37TrillionCells and specifically aims to implement Cell-based Interceptive Medicine in Quebec and Canada. The InterCEpt consortium initially brings together academic participants at the McGill University Health Center (MUHC), the Research Center of the Centre Hospitalier de l'Université de Montréal (CRCHUM), the Research Center of the Hôpital Sacré-Coeur de Montréal (CRHSCM ), the Hospital for Sick Children of the University of Toronto, and the Institut de Recherches Cliniques de Montréal (IRCM). Discussions are underway with the Leukodystrophy Foundation (Quebec) and the Lifetime Initiative to establish official partnerships, via 37TrillionCells.
Towards Cell-based Interceptive Medicine: Combining proteome profiling and phage display to track the phenotypic trajectory of cells during diabetes (funded by the Ministry of Economy and Innovation (MEI)-IRCM strategic initiative)
Spring 2023 (date to be announced)